Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
29
08
2021
accepted:
17
11
2021
revised:
25
10
2021
pubmed:
17
12
2021
medline:
26
4
2022
entrez:
16
12
2021
Statut:
ppublish
Résumé
MiR-371a-3p predicts the presence of a macroscopic non-teratomatous germ cell tumour (GCT). We hypothesised that miR-371a-3p can also detect recurrence during active surveillance (AS) of stage I GCT. We prospectively collected serum samples of 33 men. Relative expression of serum miR-371a-3p levels was determined at each follow-up visit using real-time quantitative reverse transcription-polymerase chain reaction. Recurrence was detected using standard follow-up investigations in 10/33 patients (30%) after a median of 7 months. Directly after orchiectomy, miR-371a-3p levels were not elevated in any of the 15 patients with available post-orchiectomy samples. However, all ten recurring patients exhibited increasing miR-371a-3p levels during follow-up, while miR-371a-3p levels remained non-elevated in all but one patient without recurrence. MiR-371a-3p detected recurrences at a median of 2 months (range 0-5) earlier than standard follow-up investigations. MiR-371a-3p levels immediately post orchiectomy are not predictive for recurrences and unfortunately cannot support decision-making for AS vs. adjuvant treatment. However, miR-371a-3p detects recurrences reliably and earlier than standard follow-up investigations. If this can be confirmed in larger cohorts, monitoring miR-371a-3p could replace surveillance imaging in seminomatous GCT and reduce the amount of imaging in non-seminomatous GCT. Earlier detection of disease recurrence may also reduce the overall treatment burden.
Sections du résumé
BACKGROUND
MiR-371a-3p predicts the presence of a macroscopic non-teratomatous germ cell tumour (GCT). We hypothesised that miR-371a-3p can also detect recurrence during active surveillance (AS) of stage I GCT.
METHODS
We prospectively collected serum samples of 33 men. Relative expression of serum miR-371a-3p levels was determined at each follow-up visit using real-time quantitative reverse transcription-polymerase chain reaction.
RESULTS
Recurrence was detected using standard follow-up investigations in 10/33 patients (30%) after a median of 7 months. Directly after orchiectomy, miR-371a-3p levels were not elevated in any of the 15 patients with available post-orchiectomy samples. However, all ten recurring patients exhibited increasing miR-371a-3p levels during follow-up, while miR-371a-3p levels remained non-elevated in all but one patient without recurrence. MiR-371a-3p detected recurrences at a median of 2 months (range 0-5) earlier than standard follow-up investigations.
CONCLUSIONS
MiR-371a-3p levels immediately post orchiectomy are not predictive for recurrences and unfortunately cannot support decision-making for AS vs. adjuvant treatment. However, miR-371a-3p detects recurrences reliably and earlier than standard follow-up investigations. If this can be confirmed in larger cohorts, monitoring miR-371a-3p could replace surveillance imaging in seminomatous GCT and reduce the amount of imaging in non-seminomatous GCT. Earlier detection of disease recurrence may also reduce the overall treatment burden.
Identifiants
pubmed: 34912073
doi: 10.1038/s41416-021-01643-z
pii: 10.1038/s41416-021-01643-z
pmc: PMC9023438
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN371 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1140-1144Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2014. https://doi.org/10.1200/jco.2014.56.2116 .
Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol. 2009;181:627–32. discussion 632–623.
doi: 10.1016/j.juro.2008.10.005
pubmed: 19091344
Huang MM, Su ZT, Cheaib JG, Biles MJ, Allaf ME, Patel HD, et al. Cost-effectiveness analysis of non-risk-adapted active surveillance for postorchiectomy management of clinical stage I seminoma. Eur Urol Focus. 2020. https://doi.org/10.1016/j.euf.2020.06.012 .
Almstrup K, Lobo J, Mørup N, Belge G, Rajpert-De Meyts E, Looijenga LH, et al. Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nat Rev Urol. 2020;17:201–13.
doi: 10.1038/s41585-020-0296-x
pubmed: 32157202
Rothermundt C, Thurneysen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, et al. Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). Swiss Med Wkly. 2018;148:w14640.
pubmed: 30044478
Murray MJ, Bell E, Raby KL, Rijlaarsdam MA, Gillis AJ, Looijenga LH, et al. A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. Br J Cancer. 2016;114:151–62.
doi: 10.1038/bjc.2015.429
pubmed: 26671749
Bell E, Watson HL, Bailey S, Murray MJ, Coleman N. A robust protocol to quantify circulating cancer biomarker microRNAs. Methods Mol Biol. 2017;1580:265–79.
doi: 10.1007/978-1-4939-6866-4_18
pubmed: 28439839
Blondal T, Nielsen SJ, Baker A, Andreasen D, Mouritzen P, Teilum MW, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013;59:S1–S6.
doi: 10.1016/j.ymeth.2012.09.015
pubmed: 23036329
Murray MJ, Halsall DJ, Hook CE, Williams DM, Nicholson JC, Coleman N. Identification of microRNAs From the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am J Clin Pathol. 2011;135:119–25.
doi: 10.1309/AJCPOE11KEYZCJHT
pubmed: 21173133
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001;25:402–8.
doi: 10.1006/meth.2001.1262
pubmed: 11846609
Myklebust MP, Rosenlund B, Gjengstø P, Bercea BS, Karlsdottir Á, Brydøy M, et al. Quantitative PCR measurement of miR-371a-3p and miR-372-p is influenced by hemolysis. Front Genet. 2019;10:463–463.
doi: 10.3389/fgene.2019.00463
pubmed: 31191602
pmcid: 6539204
Dieckmann K-P, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, et al. Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol. 2019;37:1412.
doi: 10.1200/JCO.18.01480
pubmed: 30875280
pmcid: 6544462
Lobo J, Leão R, Gillis AJ, van den Berg A, Anson-Cartwright L, Atenafu EG, et al. Utility of serum miR-371a-3p in predicting relapse on surveillance in patients with clinical stage I testicular germ cell cancer. Eur Urol Oncol. 2021;4:483–91.
doi: 10.1016/j.euo.2020.11.004
pubmed: 33288479
van Agthoven T, Looijenga LH. Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test). Oncotarget. 2017;8:58037.
doi: 10.18632/oncotarget.10867
pubmed: 28938535
Radtke A, Cremers J-F, Kliesch S, Riek S, Junker K, Mohamed S, et al. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p? J Cancer Res Clin Oncol. 2017;143:2383–92.
doi: 10.1007/s00432-017-2490-7
pubmed: 28819887
pmcid: 5640733
Terbuch A, Adiprasito JB, Stiegelbauer V, Seles M, Klec C, Pichler GP, et al. MiR-371a-3p serum levels are increased in recurrence of testicular germ cell tumor patients. Int J Mol Sci. 2018;19:3130.
doi: 10.3390/ijms19103130
pmcid: 6213366
Hiester A, Nini A, Arsov C, Buddensieck C, Albers P. Robotic assisted retroperitoneal lymph node dissection for small volume metastatic testicular cancer. J Urol. 2020;204:1242–8.
doi: 10.1097/JU.0000000000001301
pubmed: 32717162
Papachristofilou A, Bedke J, Hayoz S, Fischer N, Schiel X, Schratzenstaller U, et al. Treatment compliance and early toxicity in SAKK 01/10: single-dose carboplatin and involved-node radiotherapy for treatment of stage IIA/B seminoma. Alexandria, VA: American Society of Clinical Oncology; 2020.
Afferi L, Baumeister P, Fankhauser C, Mordasini L, Moschini M, Aschwanden F, et al. Nerve-sparing robot-assisted retroperitoneal lymph node dissection: the monoblock technique. Eur Urol Open Sci. 2021;32:1–7.
doi: 10.1016/j.euros.2021.07.004
pubmed: 34667953
pmcid: 8505201